Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
Hoffmann-La Roche
Jeffrey S Heier; Arshad M Khanani; Carlos Quezada Ruiz; Karen Basu; Philip J Ferrone; Christopher Brittain; Marta S Figueroa; Hugh Lin; Frank G Holz; Vaibhavi Patel; Timothy Y Y Lai; David Silverman; Carl Regillo; Balakumar Swaminathan; Francesco Viola; Chui Ming Gemmy Cheung; Tien Y Wong; TENAYA and LUCERNE Investigators